和元生物：2025年同比亏损10,109.73万元

Core Viewpoint - The company reported a revenue of 267.66 million yuan for 2025, reflecting a year-on-year growth of 7.86%, while it faced a net loss attributable to shareholders of 220.72 million yuan, which is a reduction in loss by 101.10 million yuan compared to the previous year [1] Financial Performance - The company achieved a revenue of 267.66 million yuan in 2025, marking a 7.86% increase from the previous year [1] - The net profit attributable to shareholders was -220.72 million yuan, showing a decrease in loss by 101.10 million yuan year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -232.02 million yuan, which is a reduction in loss by 103.89 million yuan compared to the same period last year [1] Industry Context - The domestic biopharmaceutical sector is characterized by a complex landscape of intertwined opportunities and challenges, with diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1]